论文部分内容阅读
目的 :探讨细胞角蛋白片段 2 1 1(CYFRA2 1 1)在喉癌患者血清中的表达及其临床意义。方法 :采用酶联免疫吸附法对 2 5例喉癌患者手术前后的血清CYFRA2 1 1进行检测 ,并与 2 0例喉良性病变患者进行对比。结果 :喉癌患者血清CYFRA2 1 1阳性率为 6 0 .0 % ,术前CYFRA2 1 1水平为 (5 .14± 1.82 ) μg/L ,显著高于喉良性病变 (2 .17± 0 .6 8) μg/L(P <0 .0 5 )。术后血清CYFRA2 1 1水平显著下降并低于正常水平。术后复发者血清CYFRA2 1 1水平再次上升。CYFRA2 1 1含量与喉癌患者的年龄、性别及肿瘤部位无关 ;高水平血清CYFRA2 1 1与喉癌临床分期、病理分级及淋巴结转移相关 ,分化愈差 ,CYFRA2 1 1含量越高。结论 :血清CYFRA2 1 1可望作为喉癌诊断、预后判定和术后随访有用的生物学指标。
Objective: To investigate the expression of cytokeratin 21 (CYFRA2 1 1) in serum of laryngeal cancer patients and its clinical significance. Methods: The serum levels of CYFRA2 1 1 in 25 cases of laryngeal carcinoma before and after operation were detected by enzyme-linked immunosorbent assay and compared with 20 cases of laryngeal benign lesions. Results: The positive rate of serum CYFRA2 1 1 in laryngeal cancer patients was 60.0%. The preoperative level of CYFRA2 1 1 was (5.114 ± 1.82) μg / L, which was significantly higher than that in benign laryngeal lesions (2.17 ± 0.6 8) μg / L (P <0.05). Postoperative serum levels of CYFRA2 1 1 were significantly lower than normal. Postoperative recurrence of serum CYFRA2 1 1 levels rise again. The CYFRA2 1 1 content was not related to the age, sex and tumor location of the patients with laryngeal cancer. The high level of serum CYFRA2 1 1 was associated with the clinical stage, pathological grade and lymph node metastasis of laryngeal cancer. The worse the differentiation, the higher the CYFRA2 1 1 content. Conclusion: Serum CYFRA2 1 1 is expected to be a useful biomarker for the diagnosis, prognosis and follow-up of laryngeal cancer.